Umang Vohra - Dr Reddys President

<div class='logoBackup' style='background:#754DEB;color: white;font-size:4em;padding-top: 15px;;'>DR</div>
RDY -- USA Stock  

USD 41.89  0.63  1.53%

  President
Mr. Umang Vohra is Executive Vice President Head North America Generics of Dr. Reddy Laboratories Ltd since January 2013. He resigned as Chief Financial Officer of the company effective January 2 2013. He has over 14 years of experience across various functions within finance strategic planning and corporate development. He is responsible for managing Company organizations global finance functions including among others Accounts and Controlling Taxation Compliance Secretarial Investor Relations and Treasury. He joined the Company in 2002 initially working as Deputy Chief Financial Officer and was part of several of Company key initiatives like acquisitions research and development derisking transactions and operational improvements and migration to IFRS in Company accounting governance and finance processes. Prior to joining the Company Mr. Vohra worked with Eicher and PepsiCo India
Age: 43  President Since 2013  MBA    
91 40 4900 2900  http://www.drreddys.com
Vohra has a base degree in computer engineering and he holds an MBA with a specialization in Finance from TA Pai Institute of Management, India.

Management Efficiency

The company has Return on Asset of 6.98 % which means that on every $100 spent on asset it made $6.98 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 18.75 % implying that it generated $18.75 on every 100 dollars invested.
The company has 811.73 M in debt with debt to equity (D/E) ratio of 20.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Dr Reddys Laboratories has Current Ratio of 1.92 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

PRESIDENT Since

Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Jay MarkowitzRegeneron Pharmaceuticals
2017
Douglas BoothePerrigo Company Plc
2013
John GrayVertex Pharmaceuticals Incorpor
2019
Joyce LeeZoetis
2012
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Scott JamisonPerrigo Company Plc
2011
Grainne QuinnPerrigo Company Plc
2016
Glenn DavidZoetis
2016
Sandra BeatyZoetis
2012
Amit SachdevVertex Pharmaceuticals Incorpor
2017
Paul WeningerPerrigo Company Plc
2015
Andrew FentonZoetis
2018
Svend AndersenPerrigo Company Plc
2017
Peter PowchikRegeneron Pharmaceuticals
2006
John WesolowskiPerrigo Company Plc
2016
Alejandro BernalZoetis
2015
Joseph LaRosaRegeneron Pharmaceuticals
2019
Marc CouckePerrigo Company Plc
N/A
Jatin ShahPerrigo Company Plc
2005

Entity Summary

Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 21966 people.Dr Reddys Laboratories Ltd (RDY) is traded on BATS Exchange in USA and employs 21,966 people.

Dr Reddys Laboratories Leadership Team

G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
MARC KIKUCHI, Chief Executive Officer, North America Generics
Hans Hasler, Additional Independent Director
Leo Puri, Non-Executive Independent Director
Sandeep Poddar, Compliance Officer, Company Secretary
Satish Reddy, Co-Chairman of the Board
Kedar Upadhye, IR Contact Officer
Samiran Das, Executive Vice President Head - FTO and GGPM
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization
YUGANDHAR PUVVALA, Global Head of Supply Chain
Amit Biswas, Executive Vice President - Integrated Product Development
Ravi Bhoothalingam, Non-Executive Independent Director
Alok Sonig, Senior Vice President & India Business Head (Generics)
Allan Oberman, Non-Executive Independent Director
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives
Prasad Menon, Lead Non-Executive Independent Director
K Rao, Sr. Vice President & Head ? Chemical Technical Operations (CTO)
Abhijit Mukherjee, COO
Anil Namboodiripad, Global Head of Proprietary Products
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE
SANJAY SHARMA, Global Head of Manufacturing
Shikha Sharma, Non-Executive Independent Director
Sridar Iyengar, Non-Executive Independent Director
Ganadhish Kamat, Executive Vice President and Global Head-Quality
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council
Omkar Goswami, Non-Executive Independent Director
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI
Kalpana Morparia, Non-Executive Independent Director
Bharat Doshi, Non-Executive Independent Director
J Moreau, Non-Executive Independent Director
Raymond Vre, Global Head of Biologics
Raghav Chari, Senior Vice President - Proprietary Products
Bruce Carter, Non-Executive Independent Director
Saunak Savla, IR Contact Officer
Ashok Ganguly, Non-Executive Independent Director
Umang Vohra, Executive Vice President Head - North America Generics
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)
Cartikeya Reddy, Senior Vice President Head - Biologics
Anupam Puri, Non-Executive Independent Director
Archana Bhaskar, Chief Human Resource Officer
Deepak Sapra, Global Head of PSAI

Stock Performance Indicators

window.location = "/error404.html";